PARSIPPANY, N.J., Aug. 2, 2011 /PRNewswire/ — Pacira
Pharmaceuticals, Inc. (Nasdaq:
PCRX), an emerging specialty pharmaceutical company, today
announced that new preclinical data evaluating the safety of
DepoFoam® with DEPC (a novel excipient) will be presented in
two podium sessions at the 38th Annual Meeting & Exposition of
the Controlled Release Society (CRS) in National Harbor, Md.
DepoFoam is Pacira’s proprietary, extended release drug delivery
technology, which is a key component of EXPAREL™ (bupivacaine
extended-release liposome injection), the company’s lead
investigational product candidate for postsurgical pain
management.
The first abstract, titled “Quantitative WholeBody
Autoradiography Following Single Subcutaneous Injection of [114C]
2erucoyl)DEPC DepoFoam Formulation in Rats,” will be presented on
Tuesday, August 2, 2011, at 4:30 p.m. EDT. The second
abstract, titled “Safety Evaluation of a Novel Pharmaceutical
Excipient (DEPC) in EXPAREL, an Extended-Release Liposomal
Formulation of Bupivacaine,” will be presented on Tuesday, August
2, 2011, at 5 p.m. EDT. Both abstracts are being presented at a
major medical meeting for the first time.
“These new data add to the growing body of evidence supporting
the safety of DepoFoam as a proprietary, extended release drug
delivery technology,” said David Stack, president and chief
executive officer of Pacira Pharmaceuticals, Inc. “As DepoFoam is
the carrier vehicle for our lead product candidate, EXPAREL, these
presentations mark another important safety milestone for the
clinical community. We believe these data, combined with the other
positive clinical and pre-clinical data we have previously
presented, further validate the potential safety and utility of
EXPAREL in postsurgical pain management, should it be approved by
the Food and Drug Administ
‘/>”/>
